Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medroxyprogesterone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 0.96 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.96 |
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.96 |
| ▸ | AR | P10275 | 4/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.96 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 2/20 | 0.96 |
| ▸ | SHBG | P04278 | 2/20 | 0.96 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.96 |
| ▸ | ESR1 | P03372 | 1/20 | 0.96 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.96 |
| ▸ | HRH2 | P25021 | 1/20 | 0.96 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.96 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.96 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medroxyprogesterone Acetate SCHEMBL4556265 | 1.00 | NR3C1 (0.96) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL5493761 | 1.00 | NR3C1 (0.96) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL8987454 | 1.00 | NR3C1 (0.96) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL10080145 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL3892232 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL6835475 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL4276 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL6563018 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL22761990 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR | |
| Medroxyprogesterone Acetate SCHEMBL13941346 | 0.98 | NR3C1 (1.00) | NR3C1LMNACYP3A4PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34198 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122084582-A | Auxiliary kit for detecting content of calcium ions in cells | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026097604-A1 | COMPOSITION AND DRUG-DEVICE COMBINATION PRODUCT FOR LOCAL TUMOR ADMINISTRATION, AND USE | 诺曼德美国有限责任公司 | 2026-05-15 | — | — | WO | claimed |
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-0163489-A1 | Treatment of female hair loss | Mortimer, Christopher Harry, Dr. (GB) | 1985-12-04 | — | — | EP | claimed |
| EP-0136781-A2 | Treatment of endometriosis | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-04-10 | — | — | EP | claimed |
| EP-0123528-A1 | Pharmaceutical composition for the treatment of hair loss | Mortimer, Christopher Harry, Dr. (GB) | 1984-10-31 | — | — | EP | claimed |
| WO-1984004038-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HAIR LOSS | MORTIMER CHRISTOPHER HARRY (GB) | 1984-10-25 | — | — | WO | claimed |
| EP-0114003-A1 | Antiandrogen and antibiotic treatment of acne and pharmaceutical preparations therefor | Mortimer, Christopher Harry, Dr. (GB) | 1984-07-25 | — | — | EP | claimed |
| US-4310510-A | Self administrable anti-fertility composition | SHERMAN KENNETH N | 1982-01-12 | — | — | US | claimed |
| US-4252787-A | CONTRACEPTIVES, PROGESTATIONAL ACTIVITY, STEROIDS | CAMBRIDGE RESEARCH AND DEVELOPMENT GROUP (US) | 1981-02-24 | — | — | US | claimed |
| US-4038389-A | VEHICLE FOR PARENTERAL ADMINISTRATION | THE UPJOHN COMPANY (US) | 1977-07-26 | — | — | US | claimed |
| US-3942641-A | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-03-09 | — | — | US | claimed |
| US-3932635-A | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-01-13 | — | — | US | claimed |